drugset
drugset / Trial / NCT02451930

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

NCT02451930 ↗

Phase 1 Completed 71 enrolled Eli Lilly and Company Merck Sharp & Dohme LLC · collab
NaSequentialOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).

Timeline

Start
2015-09-04
Primary completion
2017-01-26
Completion
2019-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Necitumumab Monoclonal antibody 600 mg Intravenous
Subject Necitumumab Monoclonal antibody 800 mg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma